
| Pair Name | Norizalpinin, Cisplatin | ||
| Phytochemical Name | Norizalpinin (PubChem CID: 5281616 ) | ||
| Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
| Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
| Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
||
| Pair Name | Norizalpinin, Cisplatin | |||
| Disease Info | [ICD-11: 2A60.Z] | Acute myeloid leukemia | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| In Vitro Model | HL-60 | Adult acute myeloid leukemia | Homo sapiens (Human) | CVCL_0002 |
| L1210 | Leukemia | Mus musculus (Mouse) | CVCL_0382 | |
| Result | We assume that tested flavonoids affect the important biological activities connected with cancer chemotherapy and chemoprevention as they differently modulated the sensitivity of cells to cis-Pt treatment. QU is presented as pro-apoptotic agent and GA as agent with anti-apoptotic potential. | |||
| Pair Name | Norizalpinin, Cisplatin | |||
| Disease Info | [ICD-11: 2C25.Z] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Expression | BID | hsa637 | |
| Down-regulation | Expression | RELA | hsa5970 | |
| Down-regulation | Expression | STAT3 | hsa6774 | |
| In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
| In Vivo Model | A549/DDP cells were harvested, 5×10⁶ cells were in jected subcutaneously into the right oxter of mice | |||
| Result | Our data indicated a novel therapeutic strategy to potentiate DDP-induced anti-tumor effect in lung cancer cells with DDP resistance by GG through inactivating p-STAT3/p65 and Bcl-2 pathways. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Effects of flavonoids on cisplatin-induced apoptosis of HL-60 and L1210 leukemia cells. Leuk Res. 2003 Jan;27(1):65-72. doi: 10.1016/s0145-2126(02)00063-2. | Click |
| 2 | Galangin (GG) combined with cisplatin (DDP) to suppress human lung cancer by inhibition of STAT3-regulated NF-κB and Bcl-2/Bax signaling pathways. Biomed Pharmacother. 2018 Jan;97:213-224. doi: 10.1016/j.biopha.2017.10.059. | Click |